Aprea Therapeutics Inc. (APRE) Financial Statements (2025 and earlier)

Company Profile

Business Address 3805 OLD EASTON ROAD
DOYLESTOWN, PA 18902
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28,694,69432,369,97321,606,82025,353,51327,685,13130,995,714
Cash and cash equivalents28,694,69432,369,97321,606,82025,353,51327,685,13130,995,714
Other undisclosed current assets865,092698,864914,275286,263953,6701,022,803
Total current assets:29,559,78633,068,83722,521,09525,639,77628,638,80132,018,517
Noncurrent Assets
Property, plant and equipment92,37990,18388,36286,1981,6871,912
Restricted cash and investments41,26040,98640,71740,44940,180 
Other noncurrent assets271,162     
Total noncurrent assets:404,801131,169129,079126,64741,8671,912
TOTAL ASSETS:29,964,58733,200,00622,650,17425,766,42328,680,66832,020,429
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,802,7391,956,6893,000,0562,251,0722,694,1263,129,623
Accounts payable964,3271,318,3851,670,369862,5521,131,197826,027
Accrued liabilities838,412638,3041,329,6871,388,5201,562,9292,303,596
Deferred revenue 50,739148,405528,974   
Other undisclosed current liabilities1,240,751859,982856,5751,914,9901,256,6951,097,765
Total current liabilities:3,094,2292,965,0764,385,6054,166,0623,950,8214,227,388
Noncurrent Liabilities
Liabilities, other than long-term debt100,000100,000100,000100,000  
Liability for uncertainty in income taxes100,000100,000100,000100,000  
Total noncurrent liabilities:100,000100,000100,000100,000  
Total liabilities:3,194,2293,065,0764,485,6054,266,0623,950,8214,227,388
Equity
Equity, attributable to parent25,559,29528,923,86716,953,50620,289,29823,418,78426,481,978
Common stock5,4305,4303,7363,7363,7313,731
Additional paid in capital350,545,473350,438,045335,644,204335,561,343335,485,317335,215,994
Accumulated other comprehensive loss(10,628,304)(10,626,356)(10,611,273)(10,635,874)(10,634,872)(10,561,452)
Accumulated deficit(314,363,304)(310,893,252)(308,083,161)(304,639,907)(301,435,392)(298,176,295)
Other undisclosed equity     1,311,0631,311,063
Total equity:25,559,29528,923,86716,953,50620,289,29824,729,84727,793,041
Other undisclosed liabilities and equity1,211,0631,211,0631,211,0631,211,063  
TOTAL LIABILITIES AND EQUITY:29,964,58733,200,00622,650,17425,766,42328,680,66832,020,429

Income Statement (P&L) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Operating expenses(4,408,498)(3,530,239)(3,689,004)(3,842,318)(3,901,369)(4,622,503)
Other undisclosed operating income561,574380,56914,075319,468249,688 
Operating loss:(3,846,924)(3,149,670)(3,674,929)(3,522,850)(3,651,681)(4,622,503)
Nonoperating income371,370339,579231,675318,335392,584242,613
Other nonoperating income376,872339,579231,675318,335392,584242,613
Net loss:(3,475,554)(2,810,091)(3,443,254)(3,204,515)(3,259,097)(4,379,890)
Other undisclosed net income attributable to parent5,502     
Net loss available to common stockholders, diluted:(3,470,052)(2,810,091)(3,443,254)(3,204,515)(3,259,097)(4,379,890)

Comprehensive Income (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(3,475,554)(2,810,091)(3,443,254)(3,204,515)(3,259,097)(4,379,890)
Comprehensive loss:(3,475,554)(2,810,091)(3,443,254)(3,204,515)(3,259,097)(4,379,890)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,554(15,083)24,601(1,002)(73,420)61,956
Comprehensive loss, net of tax, attributable to parent:(3,472,000)(2,825,174)(3,418,653)(3,205,517)(3,332,517)(4,317,934)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: